How the Piper Sandler Virtual Fireside Chat Puts Ocular Therapeutix in Focus

The recent Piper Sandler Virtual Fireside Chat brought Ocular Therapeutix (OCUL) back onto investor radar, prompting a closer look at how the stock’s recent returns line up with the company’s current financial profile.

At a share price of US$10.78, Ocular Therapeutix has seen a 30 day share price return of 26.75% and a 90 day share price return of 30.04%. However, its year to date share price return is still down 8.80% and the 1 year total shareholder return is down 9.18%, while the 3 year total shareholder return is up strongly, suggesting recent momentum is building from a longer period of volatility.

If the renewed interest around Ocular Therapeutix has you thinking more broadly about where capital could work next, it may be worth scanning the market using the 40 healthcare AI stocks.

Ocular Therapeutix now trades at a steep discount to analyst targets after a sharp 30 day move. Is that a sign the market is too cautious about its loss making profile, or a reminder that the recent optimism is fragile?

Most Popular Narrative: 60.2% Undervalued

At a last close of $10.78 against a narrative fair value of $27.09, Ocular Therapeutix is framed as heavily undervalued, which explains why the current debate is centered on Axpaxli and its potential to reshape the story.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6 to 12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

Want to see what sits underneath that kind of upside case? The narrative leans on rapid revenue expansion, rising margins, and a premium future earnings multiple. Curious which specific assumptions push the fair value all the way to $27.09?

Result: Fair Value of $27.09 (UNDERVALUED)

However, Ocular Therapeutix still hinges heavily on Axpaxli. As a result, any setback in key trials or tighter pricing pressure could quickly challenge that upbeat valuation story.

Another View: What Multiples Say About Ocular Therapeutix

The fair value narrative around Ocular Therapeutix points to a large upside, yet the market is currently paying a very high P/S ratio of 45.5x. That compares with 5.4x for the wider US Pharmaceuticals industry and a fair ratio estimate of just 0.1x. This raises the question of whether that gap reflects opportunity or valuation risk if sentiment cools.

Next Steps

If the mix of optimism and caution around Ocular Therapeutix leaves you unsure, take a closer look at the data now and shape your own view with the 2 key rewards and 3 important warning signs.

Looking For More Investment Ideas Beyond Ocular Therapeutix?

If Ocular Therapeutix has sharpened your focus, do not stop here. Broader ideas can help balance your portfolio and reveal opportunities you might otherwise miss.

• Target reliable income streams by checking companies that show up in the 12 dividend fortresses.
• Spot potential value opportunities early by reviewing the screener containing 18 high quality undiscovered gems before others catch on.
• Prioritise capital preservation and steadier profiles by scanning the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.